肿瘤药学2018，Vol.8Issue(2)：170-173,4.DOI:10.3969/j.issn.2095-1264.2018.02.09
含贝伐珠单抗化疗方案对转移性非小细胞肺癌患者血小板的影响
Effect of Chemotherapy with Bevacizumab on Platelet Parameters in Patients with Metastatic Non-small Cell Lung Cancer
摘要
Abstract
Objective To evaluate the effect of regimens containing bevacizumab on platelet parameters of patients with metastatic non-small cell lung cancer (NSCLC). Methods A total of 58 patients with metastatic NSCLC were recruited, and all of them were given Beva-cizumab chemotherapy. Their clinical data were retrospectively analyzed. Their platelet counts (PLTs), platelet distribution width (PDW), mean platelet volume (MPV), platelet–large-cell ratio (P-LCR), and platecrit (PCT) values at baseline and after three months of chemo-therapy were recorded in the SPSS 18.0 program. Results PCT significantly decreased during treatment with bevacizumab (P=0.024). Subgroup analysis revealed that PLTs significantly decreased in the male group and ≥60-year-old group (P=0.022, 0.012). The PCT was significantly diminished in the male group and first-line chemotherapy group (P=0.015, 0.004). After treatment, one case of subcutaneous bleeding (3.03%) occurred in the first-line chemotherapy group, and one case of pulmonary hemorrhage (4.00%) occurred in the second line chemotherapy group. The total incidence of bleeding was 3.44%. Conclusion The chemotherapy regimens containing bevacizumab could decrease PCT of patients with metastatic NSCLC.关键词
血小板/血小板压积/非小细胞肺癌/贝伐珠单抗Key words
Platelets/Platecrit/Non-small cell lung cancer/Bevacizumab分类
医药卫生引用本文复制引用
周洋媚,杨丽,孙伟,沈倩,刘东伯..含贝伐珠单抗化疗方案对转移性非小细胞肺癌患者血小板的影响[J].肿瘤药学,2018,8(2):170-173,4.基金项目
国家自然科学基金资助项目(81773231). （81773231）
